Autoimmune Coverage and Expertise

Treatment choice for autoimmune diseases is continually expanding. Whilst biologic originators remain firmly established across many indications, they now face growing competition. In several markets payor pressure has led to rapid biosimilar uptake. Additionally, oral advanced therapies now regularly enter the market with the goal of occupying a pre-biologic position.

As a result, some autoimmune indications face potential treatment saturation. Despite this, clear unmet needs remain among both physicians and patients. Such challenges are driving an acute need amongst pharmaceutical companies to develop brands with a clear competition differentiation, both in clinical trial and real-world settings. Furthermore, drug developers are increasingly targeting indications with little or no advanced therapy use to date; including Hidradenitis Suppurativa, Sjogren’s and Scleroderma.

Our portfolio of autoimmune Disease Specific Programmes™ provides real-world insights and evidence in support of developmental and existing therapies across multiple (adults and paediatric) disease areas covering rheumatology, gastroenterology, dermatology and nephrology. Additionally, from this year we will be launching a new arm of autoimmune rare diseases.

Coronavirus (COVID-19)

As we deal with the current COVID-19 pandemic, we would like to assure you that Adelphi Group are taking every step to ensure the safety and wellbeing of all our staff, families, friends and communities. All staff worldwide are working from home and following individual Government Stay at Home guidelines to do all we can to Protect the Health Services and Save Lives. (UK : https://www.gov.uk/coronavirus) We will continue to exercise ‘Business as Usual’ to ensure our work for all continues. Indeed at the beginning of this month we held an extremely successful all work from home day to test our systems and ability to continue to communicate and deliver for whatever may happen in our world. Little did we know at the time how timely this was to be, and this will be an annual business continuity measure going forward. We would also like to share with you a programme ‘I AM PATIENT‘ produced by one of our Associate Companies, Snow, emphasising the importance of pro-actively following these critically important guidelines and to take personal responsibility to help stop the spread of this deadly virus https://www.youtube.com/watch?v=jZs-F2620CI #iampatient, #stayhome Stay Safe